(NASDAQ: SPRB) Spruce Biosciences's forecast annual revenue growth rate of 84.64% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.32%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.27%.
Spruce Biosciences's revenue in 2024 is $10,089,000.On average, 2 Wall Street analysts forecast SPRB's revenue for 2024 to be $202,248,121, with the lowest SPRB revenue forecast at $202,083,525, and the highest SPRB revenue forecast at $202,453,867. On average, 2 Wall Street analysts forecast SPRB's revenue for 2026 to be $2,654,120,820, with the lowest SPRB revenue forecast at $1,057,533,412, and the highest SPRB revenue forecast at $4,250,708,228.
In 2027, SPRB is forecast to generate $1,616,380,154 in revenue, with the lowest revenue forecast at $1,616,380,154 and the highest revenue forecast at $1,616,380,154.